As of October 30, 2025, the average one-year price target for Disc Medicine is $111.09/share. The forecasts range from a low of $85.85 to a high of $160.65. The average price target represents an ...

Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, U.S. Head of SMid-Cap Biotech Equity Research here at the firm. Before we commence, for important ...

Fintel reports that on August 22, 2024, Wells Fargo initiated coverage of Disc Medicine (NasdaqGM:IRON) with a Overweight recommendation. As of August 6, 2024, the average one-year price target for ...

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Disc Medicine, Inc. stands sixth on our list and nears FDA filing for the first-ever EPP treatment. Disc ...

Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts who covers mid-cap biotech in the U.S. It is my pleasure to have the fireside ...

Wells Fargo analyst Tiago Fauth maintained a Buy rating on Disc Medicine (IRON – Research Report) yesterday and set a price target of $91.00. The company’s shares closed yesterday at $58.25. According ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Disc Medicine (IRON – Research Report) yesterday and set a price target of $132.00. The company’s shares closed yesterday at $51.27.